Forum Agenda
-
Keynote Forum: The Global Journey of China’s Innovation Drugs
-
-
Future-Driven Intelligent R&D–AI for Life Sciences and Drug Discovery
-
The Era of Superintelligent Agents for Chinese Innovative Drugs
-
Panel Discussion: AI-Empowered Four-in-One Translation Platform
-
AI-Driven Innovation Practices in Pharmaceutical Enterprises
-
AI·Intelligent Transformation: From Data Foundation to Scenario Value
-
-
Medicine-Engineering Integration and Innovative Medical Devices
-
Cross-Border Cooperation and China’s New Drug Global Expansion
-
Global Development of Pharma Enterprises and Emerging Market Cooperation
-
China-Japan Cooperation Session: Leveraging Japan’s Market to Boost Overseas Expansion Strategies
-
Legal Safeguard and Value Empowerment for Globalization of Chinese Pharma Enterprises
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
Global BD Cooperation Session for Innovative Drugs – Track 1, 2 & 3
-
Collaboration Between North American and Chinese Innovative Drug Industries
-
Biosimilars Commercialization & Global Launch Session(China Focus)
-
Protheragen Session: Global Biomedical Cross-Border Transactions
-
Clinical Development of Next-Generation Innovative Oncology Drugs
-
U.S. Biotech Tensions and the Future Road for Chinese Pharmaceutical Companies Going Global Session
-
July 23,13:30-17:30
IIT Supervision Model and China’s Innovation Efficiency Session
Stay tuned
Meeting Planning
Jie Li:Senior Vice President, Regulatory Affairs, Aeira Health; Director, All-Chain Pharmaceutical Information Research Institute, Beijing Economic-Technological Development Area
Dan Zhang:Foreign Member, Russian Academy of Engineering; Chief Scientist, PUMC Innovation Port; Professor & Chief Medical Officer, Fudan Institute of Clinical Science; Co-Chairman, Hillgene Biopharma
13:30-13:40 Opening Address
Leader of the Administrative Committee of Zhengzhou Airport Economy Zone
13:40-14:00 Gene Editing and Cell Therapies
Mingyao Liu:Director, Shanghai Key Laboratory of Regulatory Biology; Director, Institute of Biomedical Sciences, East China Normal University; Chairman, BRL Medicine
14:00-14:20 IITs and China's Clinical Research Regulatory Pathway
Chenyan Gao:Lead Scientist, Beijing Changping Laboratory; Former Division Director, Biological Products Clinical Division, Center for Drug Evaluation, NMPA
14:20-14:40 Reflections on Clinical Research in Cellular Gene Therapy in the Context of Regulations 818 and 828
Jinping Xie:Associate Professor, Institute of Regulatory Science for Medical Products, China Pharmaceutical University
14:40-15:00 Protecting Participant Rights in IITs and Registered Clinical Research
Wenlin Huang:Chairman, Doublle Bioproduct
15:00-15:20 The New Hub for the CGT Industry: Zhengzhou Airport Economy Zone, Henan-CGT Industrial Park, Zhongyuan Medical Science City
15:20-15:40 Tea break
15:40-16:10 Dialogue: Global Innovation Partnerships Built on China's IIT Research
Guest: Dan Zhang:Foreign Member, Russian Academy of Engineering; Chief Scientist, PUMC Innovation Port; Professor & Chief Medical Officer, Fudan Institute of Clinical Science; Co-Chairman, Hillgene Biopharma
Interview: Fangfang Zhu:CEO, HemaCell
16:10-16:25 Pharmaceutical Research Requirements for Registered Clinical Studies of Somatic Cell and Gene Therapy Technologies
Jing Chen:Deputy Director, Regulatory Affairs
16:25-16:40 IIT Regulation in Transition: Recent Updates and Compliance Priorities
Tingting Liu:Partner, Life Sciences & Healthcare Practice, AllBright Law Offices, Shanghai
16:40-17:30 Roundtable: Maximizing China's Innovation Efficiency Through the IIT Pathway